Jennifer H Carroll

Mrs. Jennifer H Carroll

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Closed access
PDF file
VWVictoria Jayne Whiteley
Victoria Jayne Whiteley
KMK. J. Martin‐McGill
K. J. Martin‐McGill
JCJennifer H Carroll
Jennifer H Carroll
HTH. Taylor
H. Taylor
NSNatasha Schoeler
Natasha Schoeler
T(The Ketogenic Dietitians Research Network (KDRN)
The Ketogenic Dietitians Research Network (KDRN)

10 February 2023 in Epilepsia
Verified
Journal Article
Open access
JCJennifer H Carroll
Jennifer H Carroll
JCJ. Helen Cross
J. Helen Cross
MHMary Hickson
Mary Hickson
EWEmma Williams
Emma Williams
VAVal Aldridge
Val Aldridge
ACAvril Collinson
Avril Collinson
Objective: Ketogenic diet therapy (KDT) can result in benefits (seizure‐related and non‐seizure‐related) for children with drug‐resistant epilepsy. However, clinical trials report a wide range of outcomes, making synthesis of evidence difficult, and do not adequately reflect parent views on important outcomes for their child. To address this, we established the first international parent, health professional, and researcher consensus to develop a core outcome set, guided by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative (COMET registration #1116).Methods: Ethical approval was granted (London–Surrey REC19/LO/1680). A scoping review and interviews with parents identified a comprehensive list of potentially important outcomes, followed by a two‐round online Delphi survey of parents and health professionals to prioritize outcomes of importance for inclusion in a core outcome set. This informed a stakeholder consensus meeting and consultation process to finalize the core outcome set.Results: In total, 97 outcomes were identified; 90 from the scoping review and seven from parent interviews. These were rationalized to 77 by the study advisory group, then rated in the first Delphi round by 49 parents and 96 health professionals, who suggested 12 new outcomes for rating in Round 2. Sixty‐six percent of participants (30 parents and 66 professionals) completed Round 2, where 22 outcomes met criteria for inclusion. In the consensus meeting (nine parents and 13 professionals), 27 undecided outcomes were discussed and scored; one further outcome reached consensus for inclusion. After consultation and ratification, 14 outcomes across five domains were included in the core outcome set.Significance: A core outcome set for childhood epilepsy treated with KDT has been developed, incorporating the views of international parents and professionals. Implementation in research and clinical settings will standardize outcome selection and reporting, facilitate data synthesis, and ultimately enhance the relevance of outcomes to parents, researchers, and health professionals.

25 April 2024 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
JCJennifer H Carroll
Jennifer H Carroll
TPTracey Parkin
Tracey Parkin
JCJ Helen Cross
J Helen Cross
MHMary Hickson
Mary Hickson
EWEmma Williams
Emma Williams
ACAvril Collinson
Avril Collinson
A diagnosis of drug-resistant epilepsy is life changing for a family. Ketogenic diet therapy (KDT) can offer hope when other treatments have failed. However, it often requires a significant change in daily routine and dietary habits. This qualitative descriptive study aimed to explore families' experiences of epilepsy and KDT. Parents of a child aged ≤18 years with epilepsy, currently or recently treated with KDT, were recruited from the UK and internationally via UK Ketogenic Diet (KD) centres, charities, and social media. Semi-structured interviews were audio recorded, transcribed verbatim, anonymised, coded using Nvivo (V12), and inductive thematic analysis undertaken. Twenty-one parents participated. Four themes and 12 subthemes emerged: 1. 'Epilepsy is all consuming' explored the impact of epilepsy on the family. 2. 'KD provides a window to new opportunities' explores the motivators for KDT and positive outcomes. 3. 'The reality of KD' explores day to day life and how families adapt to KD. 4. 'Looking to the future' explores the factors that may make KD easier for families. All were glad their child trialled KD, even when less successful. The importance of a support network including family, friends, charity organisations and the KD team was evident across all themes. We conclude with five recommendations to help support families in their management of KDT; Improved access to KDT and transition to adult services, access to quality education and support, enhanced variety of KD foods, regular social education and finally consideration of peer mentoring.

13 May 2022 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
JCJennifer H Carroll
Jennifer H Carroll
KMKirsty J. Martin-McGill
Kirsty J. Martin-McGill
JCJ. Helen Cross
J. Helen Cross
MHMary Hickson
Mary Hickson
EWEmma Williams
Emma Williams
ACAvril Collinson
Avril Collinson
Clinical trials on childhood epilepsy treated with ketogenic diet (KD) use a wide range of outcomes, however, patients and decision-makers often do not perceive the outcomes used as the most important. We sought parental opinion on outcomes of importance and compared these to outcomes reported in published research. Ethical approval (London-Surrey-REC19/LO/1680). A scoping review identified outcomes reported in previous studies of childhood epilepsy and KD. Parents were recruited from nine KD centres (UK), charities and social media (international), then interviewed (Jan-April 2020) to explore priority outcomes. Content analysis identified all outcomes in transcripts. Parent identified outcomes were compared with those in the scoping review. Outcomes were collated and grouped into domains according to the COMET Taxonomy. Of 2663 articles;147 met inclusion criteria. 921 verbatim outcomes were sorted into 90 discrete outcomes, reduced to 70 in consultation with the study advisory group, then classified into 21 domains. Parents (n = 21) identified 39 outcomes as important from the scoping review and seven new outcomes. They prioritised both physiological and functional outcomes in contrast to past studies, which prioritised physiological outcomes. Little consistency exists in the outcomes used in childhood epilepsy and KD research. Those traditionally used do not adequately reflect parents' important outcomes for their child. Clinical trials should consider the broader priorities of parents when choosing outcomes, in particular, functional outcomes. Identified outcomes will inform an international two-round Delphi-study with parent, professional and researcher participants to develop a core outcome set for this clinical area (COMET registration #1116).

1 May 2019 in JBI Evidence Synthesis
Verified
Journal Article
Closed access
JCJennifer H Carroll
Jennifer H Carroll
KMKirsty Martin-McGill
Kirsty Martin-McGill
HCHelen Cross
Helen Cross
MHMary Hickson
Mary Hickson
ACAvril Collinson
Avril Collinson
Review objective/question: The objective of this scoping review is to investigate the outcomes measured and reported in trials of children with refractory epilepsy treated with ketogenic diet therapy. The scoping review will aim to list the outcomes and map the associated components including intervention (type of ketogenic diet therapy), definition (if used) of the outcome, the tool or indicators used to measure the outcome, validity of tool used, the time from intervention commencement to measurement of the outcome and the reporting of the outcome. Specifically, the review question is: What outcomes are measured and reported in studies of childhood epilepsy treated with ketogenic diet therapy?

8 September 2025 in Epilepsy & Behavior
Verified
Journal Article
Open access
JCJennifer H Carroll
Jennifer H Carroll
ZSZoe Simpson
Zoe Simpson
LHLaura Healy
Laura Healy
CSClare Szwec
Clare Szwec
DHDenise Leonne Hofman
Denise Leonne Hofman
Ketogenic diet therapy (KDT) has been successfully used as an effective management option for drug resistant epilepsy (DRE) since the 1920 s. The ketogenic formulation studied here (KetoCal) is nutritionally complete, very high in fat, and low in carbohydrates and has played a crucial role in supporting the implementation of KDT for over twenty-five years. This scoping review aims to synthesise the existing literature regarding the safety, acceptability, and efficacy of the ketogenic formulation in supporting the management of DRE. PubMed, Google Scholar and Cochrane databases were searched from January 1998 to November 2024. English and Dutch language studies involving paediatric or adult participants with epilepsy who used the ketogenic formulation were included if the outcomes for the ketogenic formulation group were reported separately and could be extracted. Data extracted included: demographics, type of KD, ratio and volume of ketogenic formulation used, reported outcomes and time points at which measured. Searches identified a total of 645 articles, 41 met the inclusion criteria. Several reports suggest additional benefits of KDT plus the studied ketogenic formulation versus KDT alone on seizure frequency reduction and seizure severity. Compliance and retention rates varied across studies but appeared higher in those treated with KDT plus the ketogenic formulation. The ketogenic formulation was well tolerated with no major adverse effects reported. Palatability and convenience/ease of use was generally rated highly by patients and parents/caregivers. This review highlights the integral role of the studied ketogenic formulation in enhancing compliance, convenience, palatability, and efficacy of KDT for children and adults with DRE. In addition, an unexpected but important finding was the growing evidence for this particular ketogenic formulation's use in intensive care settings, particularly for the management of (super-)refractory status epilepticus.